Ichnos Glenmark Innovation to present phase 1 study data on Trispecific Antibody ISB 2001 at ASH Annual Meeting

New York-based Ichnos Glenmark Innovation (IGI), a clinical-stage biotech company focused on multispecifics in oncology, announced plans to present initial data from its Phase 1 study of ISB 2001 at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California. ISB 2001, IGI’s first-in-class trispecific antibody, targets BCMA and CD38 on myeloma cells and CD3 on T cells and is currently under investigation in patients with relapsed/refractory multiple myeloma (r/r MM).

Dr Lida Pacaud, Chief Medical Officer at IGI, commented, “Although recent advancements have brought new therapeutic options to multiple myeloma patients, resistance mechanisms continue to limit their efficacy, necessitating multiple lines of treatment for many patients. We are encouraged by the early data from our Phase 1 study of ISB 2001, which shows a remarkable response rate and demonstrates potential to address these challenges in heavily pretreated patients.”

The oral presentation will cover results from the dose-escalation phase of the study. The data abstract, reflecting findings up to July 2024, includes an overall response rate (ORR) of 75 per cent (9 out of 12 efficacy-evaluable patients), with one MRD-negative stringent complete response (sCR). Safety and tolerability results indicate no dose-limiting toxicities (DLTs), only one adverse event above Grade 2, and no treatment discontinuations.

Additional data and analyses will supplement the presentation at the ASH meeting.